CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of parkinson's disease, as revealed from experiments with recombinant enzymes

Drug Metabolism and Disposition

Volumn 29, Issue 11, 2001, Pages 1480-1484

  Hidestrand, Mats ^a   Oscarson, Mikael ^a   Salonen, Jarmo S ^b   Nyman, Leena ^b   Pelkonen, Olavi ^c   Turpeinen, Miia ^c   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; METHAMPHETAMINE; NORSELEGILINE; RECOMBINANT ENZYME; SELEGILINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; HUMAN; HUMAN CELL; LIVER CLEARANCE; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; PARKINSON DISEASE; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SELEGILINE;

EID: 0034772878     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant
2. A single nucleotide polymorphism of CYP2b6 found in japanese enhances catalytic activity by autoactivation
3. Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line
4. Chimeras of the human cytochrome P450 IA family produced in yeast. Accumulation in microsomal membranes, enzyme kinetics and stability
5. Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides
6. Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation
7. Physiological parameters in laboratory animals and humans
8. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6
9. Human liver microsomal cytochrome P-450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity
10. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity
11. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders
12. Biochemistry and molecular biology of the human CYP2C subfamily
13. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6
14. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites
15. CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants
16. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
17. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
18. The possible mechanisms of action of (-)deprenyl in Parkinson's disease
19. R-(-)-deprenyl (Selegiline. Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron
20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
21. Protein measurements with the Folin phenol reagent
22. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update
23. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes
24. The carbon monoxide-binding pigment of liver microsomes. I. Evidence of its hemoprotein nature
25. Genetically engineered yeast cells and their applications
26. CYP2D6 polymorphism is not crucial for the disposition of selegiline
27. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites
28. Selegiline metabolism and cytochrome P450 enzymes: In vitro study in human liver microsomes
29. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
30. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
31. Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5
32. Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography